BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8458248)

  • 1. Ceftriaxone plus conventional or single-daily dose amikacin versus ceftazidime/amikacin as empiric therapy in febrile neutropenic patients.
    Leoni F; Ciolli S; Pascarella A; Fanci R; Caporale R; Rossi Ferrini P
    Chemotherapy; 1993; 39(2):147-52. PubMed ID: 8458248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized clinical trial comparing ceftriaxone/amikacin versus ceftazidime/amikacin as initial therapy of febrile episodes in neutropenic patients.
    Yataganas X; Rombos Y; Vayopoulos G; Meletis J; Avlami A
    Chemotherapy; 1991; 37(5):376-81. PubMed ID: 1804599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftriaxone and amikacin versus ceftazidime and amikacin in febrile granulocytopenia.
    Schmid L; Jeschko M; Wilder-Smith C; Schafroth U; Thürlimann B; Pedrazzini A; Senn H
    Chemotherapy; 1991; 37(5):346-52. PubMed ID: 1804595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-daily ceftriaxone plus amikacin versus thrice-daily ceftazidime plus amikacin as empirical treatment of febrile neutropenia in children with cancer.
    Ariffin H; Arasu A; Mahfuzah M; Ariffin WA; Chan LL; Lin HP
    J Paediatr Child Health; 2001 Feb; 37(1):38-43. PubMed ID: 11168867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Ann Intern Med; 1993 Oct; 119(7 Pt 1):584-93. PubMed ID: 8363169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children.
    Charnas R; Lüthi AR; Ruch W
    Pediatr Infect Dis J; 1997 Apr; 16(4):346-53. PubMed ID: 9109134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
    Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
    Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of ceftriaxone plus amikacin, ceftazidime plus amikacin and imipenem/cilastatin in the empiric therapy of febrile granulocytopenic cancer patients.
    Liu CY; Wang FD
    Chemotherapy; 1989; 35 Suppl 2():16-22. PubMed ID: 2692982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isepamicin once daily plus ceftriaxone versus amikacin plus ceftriaxone in febrile neutropenic patients.
    Herbrecht R; Blaise D; Espinouse D; Leblond V; Sadoun A; Sauvage C; Cordonnier C; Minozzi C
    J Chemother; 1995 Jun; 7 Suppl 2():103-10. PubMed ID: 8622099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients.
    Flaherty JP; Waitley D; Edlin B; George D; Arnow P; O'Keefe P; Weinstein RA
    Am J Med; 1989 Nov; 87(5A):278S-282S. PubMed ID: 2686429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empirical antibiotic therapy in febrile neutropenic patients with single-daily dose amikacin plus ceftriaxone.
    Suwangool P; Aswapokee N; Sathapatayavongs B; Leelasuphasri S; Siritanaratkul N; Chuncharunee S; Chayakul P
    J Med Assoc Thai; 1993 Jun; 76(6):314-8. PubMed ID: 8083623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of febrile episodes in neutropenic leukemic patients with the antibiotic combinations piperacillin or ceftazidime plus amikacin: results of a randomized study.
    Fenu S; Raccah R; Santilli S; Micozzi A; Girmena C; Martino P; Avvisati G
    Chemioterapia; 1988 Oct; 7(5):323-6. PubMed ID: 3066517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey.
    Akova M; Akan H; Korten V; Biberoğlu K; Hayran M; Unal S; Kars A; Kansu E
    Int J Antimicrob Agents; 1999 Sep; 13(1):15-9. PubMed ID: 10563400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.
    Cometta A; Zinner S; de Bock R; Calandra T; Gaya H; Klastersky J; Langenaeken J; Paesmans M; Viscoli C; Glauser MP
    Antimicrob Agents Chemother; 1995 Feb; 39(2):445-52. PubMed ID: 7726513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised trial of empirical antibiotic therapy in febrile neutropenic patients with hematological disorders: ceftazidime versus azlocillin plus amikacin.
    Gibson J; Date L; Joshua DE; Young GA; Wilson A; Benn R; Benson W; Iland H; Vincent PC; Kronenberg H
    Aust N Z J Med; 1989 Oct; 19(5):417-25. PubMed ID: 2686610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meropenem versus ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients: a randomized study.
    de la Cámara R; Figuera A; Sureda A; Hermida G; Verge G; Olalla I; Fernández Rañada JM; Domingo Albos A
    Haematologica; 1997; 82(6):668-75. PubMed ID: 9580087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy.
    Hung KC; Chiu HH; Tseng YC; Wang JH; Lin HC; Tsai FJ; Peng CT
    J Microbiol Immunol Infect; 2003 Dec; 36(4):254-9. PubMed ID: 14723254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of ceftriaxone and amikacin as single daily dose for the empirical management of febrile granulocytopenic children with cancer.
    Pession A; Prete A; Paolucci G
    Chemotherapy; 1997; 43(5):358-66. PubMed ID: 9309370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.
    Hess U; Böhme C; Rey K; Senn HJ
    Support Care Cancer; 1998 Jul; 6(4):402-9. PubMed ID: 9695210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients].
    Pérez C; Sirham M; Labarca J; Grebe G; Lira P; Oliva J; Duhalde M; Ocqueteau M; Acuña G
    Rev Med Chil; 1995 Mar; 123(3):312-20. PubMed ID: 8525170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.